{"entity":{"id":"nct02979522","kind":"trial","name":"A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma","aka":[],"tldr":"A phase 1/2 trial of Brentuximab vedotin, Doxorubicin, Vinblastine and Dacarbazine in hodgkin lymphoma, run by Takeda, active and no longer recruiting.","summary":"A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma is a phase 1/2 interventional study registered as NCT02979522 by Takeda, with 59 participants enrolled, started 2017-09-06 and due to reach its primary completion in 2020-05-05. Interventions recorded: Brentuximab vedotin, Doxorubicin, Vinblastine and Dacarbazine. Results have been posted on the registry.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT02979522","url":"https://clinicaltrials.gov/study/NCT02979522"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hodgkin-lymphoma","advanced-stage-classical-hodgkin-lymphoma"],"sections":[],"technologies":["adc","cytotoxic-chemotherapy"],"targets":[],"drugs":["brentuximab-vedotin","doxorubicin","vinblastine","dacarbazine"],"companies":["takeda"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02979522","phase":"1/2","setting":"An Open-Label Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Patients With Advanced Stage Newly Diagnosed Hodgkin Lymphoma","sponsor":"Takeda","started":"2017-09-06","startedType":"actual","yearReported":2021,"enrolled":59,"enrolledBasis":"registry","outcomes":[{"endpoint":"Phase 2: Percentage of Participants Who Achieved a Complete Remission (CR) Per Independent Review Facility (IRF) Assessment Per International Working Group (IWG) Criteria at End of Treatment (EOT) Visit","primary":true,"unit":"%","arms":[{"name":"Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD","n":51,"value":75,"note":"95% CI 60 to 86; Figures from the ClinicalTrials.gov results section (first posted 2021-06-01), not from a publication"},{"name":"Phase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD","n":59,"value":76,"note":"95% CI 63 to 86"}],"source":"https://clinicaltrials.gov/study/NCT02979522?tab=results"},{"endpoint":"Phase 2: Percentage of Participants Who Achieved an Overall Response Rate (ORR) Per IRF Assessment Per IWG Criteria at EOT Visit","primary":true,"unit":"%","arms":[{"name":"Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD","n":51,"value":86,"note":"95% CI 74 to 94; Figures from the ClinicalTrials.gov results section (first posted 2021-06-01), not from a publication"},{"name":"Phase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD","n":59,"value":88,"note":"95% CI 77 to 95"}],"source":"https://clinicaltrials.gov/study/NCT02979522?tab=results"}]},"route":"/trials/nct02979522/","neighbours":{"cancer":[{"id":"advanced-stage-classical-hodgkin-lymphoma","kind":"cancer","name":"Advanced-stage classical Hodgkin lymphoma (stage III to IV)","route":"/cancers/advanced-stage-classical-hodgkin-lymphoma/"},{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"brentuximab-vedotin","kind":"drug","name":"Brentuximab vedotin","route":"/drugs/brentuximab-vedotin/"},{"id":"dacarbazine","kind":"drug","name":"Dacarbazine","route":"/drugs/dacarbazine/"},{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/"},{"id":"vinblastine","kind":"drug","name":"Vinblastine","route":"/drugs/vinblastine/"}],"company":[{"id":"takeda","kind":"company","name":"Takeda","route":"/companies/takeda/"}]}}